ISABELLA MALINOWSKI: Open Payments
NPI 1992229538 · RIVERSIDE, RI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$258 in 10 payments from 6 companies in 2025. Trend: 2023 $143 · 2024 $178 · 2025 $258
Food & beverage: $258
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 3 | $95 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $53 |
| Celltrion USA Inc. | 2 | $38 |
| Madrigal Pharmaceuticals | 1 | $26 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $24 |
| Novo Nordisk Inc | 1 | $21 |
Products named: TREMFYA, ENTYVIO, VEGZELMA, REZDIFFRA, XIFAXAN, Wegovy.
Industry payments across RI — which companies pay providers there.
